Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 19817936)

1.

Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.

Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA.

J Clin Hypertens (Greenwich). 2009 Oct;11(10):555-63. doi: 10.1111/j.1751-7176.2009.00163.x.

2.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

3.

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.

Simpson EL, Duenas A, Holmes MW, Papaioannou D, Chilcott J.

Health Technol Assess. 2009 Mar;13(17):iii, ix-x, 1-154. doi: 10.3310/hta13170. Review.

4.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

5.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

6.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

7.

Cost effectiveness of prostacyclins in pulmonary arterial hypertension.

Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA.

Appl Health Econ Health Policy. 2012 May 1;10(3):175-88. doi: 10.2165/11630780-000000000-00000. Review.

PMID:
22452448
8.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

9.

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D'Souza R, Welch K, Stein K.

Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167. Review.

10.

Evaluation of the ventricular assist device programme in the UK.

Sharples L, Buxton M, Caine N, Cafferty F, Demiris N, Dyer M, Freeman C.

Health Technol Assess. 2006 Nov;10(48):1-119, iii-iv. Review.

11.

Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.

Park KT, Perez F, Tsai R, Honkanen A, Bass D, Garber A.

J Pediatr Gastroenterol Nutr. 2011 Nov;53(5):489-96. doi: 10.1097/MPG.0b013e3182293a5e. Review.

PMID:
21694634
12.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

13.

Aliskiren: renin inhibitor for hypertension management.

Cheng JW.

Clin Ther. 2008 Jan;30(1):31-47. doi: 10.1016/j.clinthera.2008.01.011. Review.

PMID:
18343241
14.

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. Review.

15.

Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?

Mullins CD, Blak BT, Akhras KS.

Value Health. 2002 Jul-Aug;5(4):359-71. Review.

PMID:
12102698
16.

Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Chen RS, Lapuerta P.

Curr Hypertens Rep. 2000 Dec;2(6):525-9. Review.

PMID:
11062597
17.

The role of nonpharmacologic device interventions in the management of drug-resistant hypertension.

Frishman WH, Glicklich D.

Curr Atheroscler Rep. 2014 May;16(5):405. doi: 10.1007/s11883-014-0405-5. Review.

PMID:
24623177
18.

Baroreflex activation therapy for patients with drug-resistant hypertension.

Alnima T, Kroon AA, de Leeuw PW.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):955-62. doi: 10.1586/14779072.2014.931226. Epub 2014 Jul 12. Review.

PMID:
25017430
19.

A perspective on health benefits. Hypertension therapy.

Watkins JE, Weyhenmeyer JA.

IMJ Ill Med J. 1988 Dec;174(6):350-2. Review. No abstract available.

PMID:
2905356
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk